摘要
目的:通过观察善胃Ⅲ号方对胃癌前病变(PLGC)模型大鼠胃黏膜Bcl-2和Bax蛋白表达的影响,从细胞凋亡角度,探讨该方干预PLGC的作用机制。方法:80只健康Wistar大鼠随机分为空白对照组、模型对照组、阳性药物组和善胃Ⅲ号方组,每组20只,造模36周后开始给予药物干预,给药6周后,采用免疫组化法检测大鼠胃黏膜Bcl-2和Bax蛋白的表达水平。结果:善胃Ⅲ号方组胃黏膜Bcl-2蛋白的阳性表达率较模型对照组及阳性药物组均显著降低(P<0.05),而其Bax蛋白的阳性表达率较模型对照组及阳性药物组明显增高(P<0.05)。结论:善胃Ⅲ号方可能通过抑制PLGC模型大鼠胃黏膜Bcl-2蛋白的表达,并促进Bax蛋白的表达,从而促进PLGC细胞凋亡,对胃癌前病变的发展进行干预。
Objective： To investigate effect of Shanwei Prescription Ⅲ on precancerous lesions of gastric cancer （PLGC）and to verify its effect on PLGC rats Bcl-2 and Bax protein expression. Methods： Eighty clean grade Wistar rats were randomly divided into normal control group, model group, retinoic acid group and Shanwei Prescription Ⅲ group, 20 rats in every group. The immunohistochemical method was uesed to detect Bcl-2 and Bax protein expression in rat. Results： The Bcl-2 protein positive expression rate of Shanwei Prescription m group was lower than that of retinoic acid and model groups（ P 〈 0.05）. Bax protein positive expression rate of Shanwei Prescriptionm group was higher than that of model and retinoic acid groups（ P 〈 0.05）. Conclusion： Shanwei Prescription Ⅲ has a good therapeutic effect to PLGC.
出处
《汕头大学医学院学报》
2009年第3期133-134,137,F0002,共4页
Journal of Shantou University Medical College
基金
天津市应用基础及前沿技术研究计划重点项目(07JCZDJC08600)
关键词
善胃Ⅲ号方
胃癌前病变
BCL-2
BAX
Shanwei Prescription Ⅲ, precancerous lesion of gastric cancer, Bel-2, Bax
